Breaking News Instant updates and real-time market news.

MRK

Merck

$78.86

0.15 (0.19%)

18:02
05/20/19
05/20
18:02
05/20/19
18:02

Merck falls after Keytruda trial does not meet OS primary endpoint

Shares of Merck have recovered in after hours trading to $78.33 per share down 0.70%.

  • 28

    May

  • 31

    May

  • 03

    Jun

  • 17

    Jun

  • 20

    Jun

  • 20

    Jun

  • 16

    Jul

  • 30

    Jul

  • 06

    Aug

  • 20

    Sep

MRK Merck
$78.86

0.15 (0.19%)

05/13/19
ATLE
05/13/19
UPGRADE
ATLE
Overweight
Merck upgraded to Overweight from Neutral at Atlantic Equities
05/13/19
05/13/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Royal Dutch Shell (RDS.A, RDS.B) upgraded to Buy from Hold at Deutsche Bank and HSBC. 2. KB Home (KBH) upgraded to Overweight from Equal Weight at Barclays with analyst Matthew Bouley saying his firm's spring agent survey confirmed that housing fundamentals have improved and stabilized. 3. Becton Dickinson (BDX) upgraded to Overweight from Equal Weight at Barclays with analyst Kristen Stewart saying the pullback in the shares since the FDA update on drug-coated balloons on March 15, coupled with the resetting of expectations following the company's Q2 results, provides an opportunity for investors. 4. Merck (MRK) upgraded to Overweight from Neutral at Atlantic Equities. 5. Bausch Health (BHC) upgraded to Neutral from Underweight at JPMorgan with analyst Chris Schott saying while a number of challenges remain in the story given the company's high leverage and controversial Xifaxan loss of exclusivity, its EBITDA is "clearly stabilizing and should begin to grow from here." This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
05/14/19
HCWC
05/14/19
NO CHANGE
HCWC
BioLineRx has multiple catalysts coming in 2019, says H.C. Wainwright
H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating and $3 price target on BioLineRx (BLRX) after the company reported in-line Q1 results, with the analyst seeing BL-8040 continuing to deliver positive data on multiple clinical fronts. Pantginis sees "multiple catalysts across all the ongoing programs" for BioLineRx in 2019 that could end the continuing suffering of the shares, including top-line results in the second half of the year from the "Phase 2 triple combo pancreatic cancer trial of BL-8040, Keytruda and chemotherapy under the company's collaboration with Merck (MRK)."
05/16/19
JEFF
05/16/19
NO CHANGE
Target $29
JEFF
Buy
Jefferies calls Iovance 'big winner' at ASCO, sees up to 40% share rally
Jefferies analyst Biren Amin calls the data reported by Iovance Biotherapeutics (IOVA) the "big winner" for the American Society of Clinical Oncology annual meeting. The ASCO update suggests Iovance's tumor infiltrating lymphocytes therapy could open the door for cell therapy in the "lucrative" solid-tumor market, Amin tells investors in a research note. He points out the company reported that no new patients have progressed in the melanoma trial and offered first evidence of clinically meaningful durability for TIL therapy. Also, its cervical data that reported a 44% overall response rate is three-times greater than reported with Merck's (MRK) Keytruda in a similar patient population, contends Amin. He believes last night's update could drive a 30%-40% rally in shares of Iovance. The analyst keeps a Buy rating on the name with a $29 price target. Iovance in premarket trading is up 26%, or $2.97, to $14.20.

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.